Focus
STEWARDSHIP ANTIMICROBICA NEL NEONATO E NEL PICCOLO LATTANTE. Perché e come praticarla
Antimicrobial stewardship in newborns and young infante: why and how to do it
Alberto Berardi1, Monica Ficara2, Elisa Pietrella2, Alessandra Boncompagni2, Carlotta Toffoli2, Anastasia Bianchini3, Elisa Della Casa1, Caterina Spada2, Eugenio Spaggiari1, Matilde Ciccia4, Giancarlo Gargano5, Vittoria Rizzo6, Milena Azzanni7, Giacomo Biasci8, Lucia Gambini9, Serenella Bolognesi10, Giancarlo Piccinini11, Fabrizio Ferrari1 a nome del Gruppo per la Prevenzione delle Infezioni da Streptococco B della Regione Emilia-Romagna
1Terapia Intensiva Neonatale, Azienda Ospedaliero-Universitaria Policlinico, Modena; 2Scuola di Specializzazione in Pediatria, Università di Modena e Reggio Emilia, Modena; 3Chirurgia Pediatrica, Azienda Ospedaliero-Universitaria Policlinico, Modena; 4Terapia Intensiva Neonatale, Ospedale Maggiore, Bologna; 5Terapia Intensiva Neonatale, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia; 6Terapia Intensiva Neonatale e Pediatrica, Ospedale di Cesena; 7Terapia Intensiva Neonatale, Ospedale di Ferrara; 8Pediatria, Ospedale di Piacenza; 9Terapia Intensiva Neonatale, Azienda Ospedaliero-Universitaria Policlinico, Parma; 10Terapia Intensiva Neonatale, Ospedale di Rimini; 11Terapia Intensiva Neonatale, Ospedale di Ravenna
Ottobre 2017 - pagg. 493 -501
Abstract
Antimicrobial resistances are increasing worldwide, due to the misuse of antibiotic therapies
in humans as well as in animals. It is expected that within a few decades multi-resistant
pathogens will become the leading cause of death worldwide. The misuse of antibiotics
in the neonatal period depends on the lack of predictive diagnostic tests and
the peculiarity of symptoms of sepsis, which frequently are vague and unspecific at the
time of presentation. Policies to prevent the emergence of antimicrobial resistances rely
on a judicious use of antibiotics, on protocols and additional measures shared by health
care providers. This document summarizes recent indications issued in the Emilia-Romagna
subsequent to a review of the literature.
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. O’Neill j. Tackling drug-resistant infections
globally: final report and recommendations.
https://amr-review.org/sites/ default/
files/ 160518_Final%20paper_with%
20cover.pdf Accessed January 2, 2017.
2. Magiorakos AP, Srinivasan A, Carey RB,
et al. Multidrug-resistant extensively drug-resistant
and pandrug-resistant bacteria: an international
expert proposal for interim standard
definitions for acquired resistance. Clin
Microbiol Infect 2012;18:268-81.
3. Pulcini C, Bush K, Craig WA, et al. Forgotten
antibiotics: an inventory in Europe, the
United States, Canada, and Australia. Clin Infect
Dis 2012;54:268-74.
4. Berardi A, Lugli L, Rossi C, et al. Impact of
perinatal practices for early-onset group B
streptococcal disease prevention. Pediatr Infect
Dis J 2013;32:e265-71.
5. Polin RA; Committee on Fetus and Newborn.
Management of neonates with suspected
or proven early-onset bacterial sepsis. Pediatrics
2012;129:1006-15.
6. Wilson CB, NizetV, Maldonado JS. Bacterial
sepsis and meningitis. In: Remington and
Klein’s - Infectious Diseases of the Fetus and
Newborn Infant, 8th ed. Philadelphia: Elsevier
Saunders (Eds) 2015:217-72.
7. Haque KN. Definitions of bloodstream infection
in the newborn. Pediatr Crit Care
Med 2005;6(3 Suppl):S45-9.
8. Berardi A, Guidotti I, Vellani G, et al. Management
of the newborn at risk of early-onset
sepsis. Medico e Bambino 2013;32:507-
13.
9. Demarini S. Neonati e streptococco B: come
semplificarsi la vita. Medico e Bambino
2013;32:483-4.
10. Ng PC, Lam HS. Biomarkers in neonatology:
the next generation of tests. Neonatology
2012;102:145-51.
11. Schulman J, Dimand RJ, Lee HC, et al.
Neonatal intensive care unit antibiotic use.
Pediatrics 2015;135:826-33.
12. Verani JR, McGee L, Schrag SJ. Division
of Bacterial Diseases, National Center for
Immunization and Respiratory Diseases,
Centres for Disease Control and Prevention
(CDC). Prevention of perinatal group B
streptococcal disease-revised guidelines
from CDC, 2010. MMWR Recomm Rep
2010;59 (RR-10):1-36.
13. Berardi A, Cattelani C, Creti R, et al.
Group B streptococcal infections in the newborn
infant and the potential value of maternal
vaccination. Expert Rev Anti Infect Ther
2015;13:1387-99.
14. Benitz WE, Wynn JL, Polin RA. Reappraisal
of guidelines for management of neonates
with suspected early-onset sepsis. J Pediatr
2015;166:1070-4.
15. Cantoni L, Ronfani L, Da Riol R, et al.
Physical examination instead of laboratory
tests for most infants born to mothers colonized
with group B Streptococcus: support for
the Centers for Disease Control and Prevention’s
2010 Recommendations. J Pediatr
2013;163:568-73.
16. Berardi A, Fornaciari S, Rossi C, et al. Safety
of physical examination alone for managing
well-appearing neonates ≥ 35 weeks’ gestation
at risk for early-onset sepsis. J Matern
Fetal Neonatal Med 2015;28:1123-7.
17. Berardi A, Buffagni AM, Rossi C, et al.
Ferrari F. Serial physical examinations, a
simple and reliable tool for managing neonates
at risk for early-onset sepsis. World J Clin
Pediatr 2016;5:358-64.
18. Cantey JB, Sánchez PJ. Prolonged antibiotic
therapy for “culture-negative” sepsis in
preterm infants: it’s time to stop! J Pediatr
2011;159:707-8.
19. Cantey JB, Patel SJ. Antimicrobial stewardship
in the NICU. Infect Dis Clin North
Am 2014;28:247-61.
20. Greenwood C, Morrow AL, Lagomarcino
AJ, et al. Early empiric antibiotic use in preterm
infants is associated with lower bacterial
diversity and higher relative abundance
of Enterobacter. J Pediatr 2014;165:23-9.
21. Kuppala VS, Meinzen-Derr J, Morrow
AL, et al. Prolonged initial empirical antibiotic
treatment is associated with adverse outcomes
in premature infants. J Pediatr 2011;
159:720-5.
22. De Man P, Verhoeven BA, Verbrugh HA
et al. An antibiotic policy to prevent emergence
of resistant bacilli. Lancet 2000;355
(9208): 973-8.
23. Basu S. Neonatal sepsis: the gut connection.
Eur J Clin Microbiol Infect Dis 2015;34:
215-22.
24. National Institute for Health and Clinical
Excellence. Antibiotics for early-onset neonatal
infection: antibiotics for the prevention
and treatment of early-onset neonatal infection.
(CG102) London: NICE; 2012. Accessibile
a http://guidance.nice.org.uk/CG149/
Guidance/pdf/English.
25. Sivanandan S, Soraisham AS, Swarnam
K. Choice and duration of antimicrobial therapy
for neonatal sepsis and meningitis. Int J
Pediatr 2011;2011:712150.
26. Ku LC, Boggess KA, Cohen-Wolkowiez
M. Bacterial meningitis in infants. Clin Perinatol
2015;42:29-45.
27. Kim KS. Acute bacterial meningitis in infants
and children. Lancet Infect Dis 2010;10:
32-42.
28. Shah D, Sinn JK. Antibiotic regimens for
the empirical treatment of newborn infants
with necrotising enterocolitis. Cochrane Database
Syst Rev 2012;8:CD007448.
29. Hemels MA, van den Hoogen A, Verboon-
Maciolek MA, et al. Shortening the antibiotic
course for the treatment of neonatal coagulase-
negative staphylococcal sepsis: fine with
three days? Neonatology 2012;101:101-5.
30. Engle WD, Jackson GL, Sendelbach DM,
et al. Pneumonia in term neonates: laboratory
studies and duration of antibiotic therapy.
J Perinatol 2003;23:372-7.
31. Dellit TH, Owens RC, McGowan JE Jr, et
al. Guidelines for developing an institutional
program to enhance antimicrobial stewardship.
Clin Infect Dis 2007;44:159-77.
32. Hyun DY, Hersh AL, Namtu K, et al. Antimicrobial
stewardship in pediatrics how every
pediatrician can be a steward. JAMA Pediatr
2013;167:859-66.
33. Cantey JB, Lopez-Medina E, Nguyen S.
Empiric antibiotics for serious bacterial infection
in young infants: opportunities for stewardship.
Pediatr Emerg Care 2015;31: 568-71.
34. Vergnano S, Menson E, Kennea N, et al.
Neonatal infections in England: the NeonIN
surveillance network. Arch Dis Child Fetal
Neonatal Ed 2011;96:F9-F14.
35. Karlowicz MG, Buescher ES, Surka AE.
Fulminant late-onset sepsis in a neonatal intensive care unit, 1988-1997, and the impact
of avoiding empiric vancomycin therapy. Pediatrics
2000;106:1387-90
36. Chiu CH, Michelow IC, Cronin J, et al.
Effectiveness of a guideline to reduce vancomycin
use in the neonatal intensive care
unit. Pediatr Infect Dis J 2011;30:273-8.
37. Pauwels S, Allegaert K. Therapeutic drug
monitoring in neonates. Arch Dis Child 2016;
101:377-81.
38. Isaacs D. Unnatural selection: reducing
antibiotic resistance in neonatal units. Arch
Dis Child Fetal Neonatal Ed 2006;91:F72-F74.
39. Antibiotico profilassi perioperatoria nell’adulto,
Linee guida del SNLG (Sistema Nazionale
Linee Guida), ISS, accessibile a
http:// www.snlg-iss.it/cms/files/LG_AntibioticoP_
Unico_2008.pdf.
40. Vu LT, Nobuhara KK, Lee H, et al. Conflicts
in wound classification of neonatal operations.
J Pediatr Surg 2009;44:1206-11.
41. Shawn J. Rangel, Fung M, et al. Recent
trends in the use of antibiotic prophylaxis in
pediatric surgery. J Pediatr Surg 2011;46:366-
71.
42. Linea Guida di profilassi antibiotica in
chirurgia pediatrica, Ospedale Bambin Gesù,
consultabile sul sito: http://www.luigivicari.
it/med/wp-content/uploads/2012/09/lineaguida-
profilassi-antibiotica-in-chirurgia-pediatrica.
pdf.
43. Scottish Intercollegiate Guidelines
Network (SIGN). Accessibile a: http://www.
sign.ac.uk/pdf/sign104.pdf.
44. Stulberg JJ, Delaney CP, Neuhauser DV,
et al. Adherence to surgical care improvement
project measures and the association
with postoperative infections. JAMA 2010;
303:2479-85.
Corrispondenza: berardi.alberto@policlinico.mo.it